Harvest Portfolios Group Inc. Boosts Position in Zoetis Inc. $ZTS

Harvest Portfolios Group Inc. increased its stake in Zoetis Inc. (NYSE:ZTS) by 4.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 416,270 shares of the company’s stock after buying an additional 17,497 shares during the period. Harvest Portfolios Group Inc.’s holdings in Zoetis were worth $52,375,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after buying an additional 5,474,210 shares during the period. Nordea Investment Management AB increased its stake in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after buying an additional 2,179,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after buying an additional 550,859 shares during the period. Alliancebernstein L.P. increased its stake in Zoetis by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock worth $620,595,000 after buying an additional 496,320 shares during the period. Finally, Fundsmith LLP increased its stake in Zoetis by 25.3% in the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock worth $528,966,000 after buying an additional 730,300 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ZTS shares. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Piper Sandler reissued a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Morgan Stanley restated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a report on Friday. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $134.75.

Zoetis Price Performance

Shares of NYSE ZTS opened at $78.89 on Wednesday. The firm has a market cap of $33.07 billion, a PE ratio of 13.08, a PEG ratio of 1.27 and a beta of 0.87. The firm has a fifty day moving average of $110.54 and a 200 day moving average of $119.82. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by corporate insiders.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.